Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Credit NIAID-RML
Highlighted Sections
Statement on Therapies for High-Risk, Nonhospitalized Patients
The Panel has updated this statement to address the fact that the Omicron variant of concern is now the dominant SARS-CoV-2 variant in the United States.
Statement on Evusheld for PrEP
The Panel provides recommendations for using tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP) in certain individuals who, if infected, are at high risk of progressing to severe COVID-19.
Statement on Anticoagulation in Hospitalized Patients
This statement contains the Panel’s recommendations on using anticoagulation in hospitalized, nonpregnant adults with COVID-19 who are receiving supplemental oxygen.
Statement on Paxlovid Drug-Drug Interactions
This statement highlights the importance of evaluating a patient’s medication regimen for potentially serious drug-drug interactions before prescribing ritonavir-boosted nirmatrelvir (Paxlovid).
Statement on Patient Prioritization for Outpatient Therapies
The Panel offers guidance on triaging outpatients for receipt of anti-SARS-CoV-2 therapies or preventive strategies.
Statement on Therapies for High-Risk, Nonhospitalized Patients
The Panel has updated this statement to address the fact that the Omicron variant of concern is now the dominant SARS-CoV-2 variant in the United States.
Statement on Evusheld for PrEP
The Panel provides recommendations for using tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP) in certain individuals who, if infected, are at high risk of progressing to severe COVID-19.
Statement on Anticoagulation in Hospitalized Patients
This statement contains the Panel’s recommendations on using anticoagulation in hospitalized, nonpregnant adults with COVID-19 who are receiving supplemental oxygen.
Statement on Paxlovid Drug-Drug Interactions
This statement highlights the importance of evaluating a patient’s medication regimen for potentially serious drug-drug interactions before prescribing ritonavir-boosted nirmatrelvir (Paxlovid).
Statement on Patient Prioritization for Outpatient Therapies
The Panel offers guidance on triaging outpatients for receipt of anti-SARS-CoV-2 therapies or preventive strategies.
Statement on Therapies for High-Risk, Nonhospitalized Patients
The Panel has updated this statement to address the fact that the Omicron variant of concern is now the dominant SARS-CoV-2 variant in the United States.
Statement on Evusheld for PrEP
The Panel provides recommendations for using tixagevimab plus cilgavimab (Evusheld) as pre-exposure prophylaxis (PrEP) in certain individuals who, if infected, are at high risk of progressing to severe COVID-19.
Statement on Anticoagulation in Hospitalized Patients
This statement contains the Panel’s recommendations on using anticoagulation in hospitalized, nonpregnant adults with COVID-19 who are receiving supplemental oxygen.
Statement on Paxlovid Drug-Drug Interactions
This statement highlights the importance of evaluating a patient’s medication regimen for potentially serious drug-drug interactions before prescribing ritonavir-boosted nirmatrelvir (Paxlovid).
Statement on Patient Prioritization for Outpatient Therapies
The Panel offers guidance on triaging outpatients for receipt of anti-SARS-CoV-2 therapies or preventive strategies.